Treatment of atopic dermatitis with a combination of allergen-specific immunotherapy and a histamine-immunoglobulin complex.
Allergic responses to common environmental agents are believed to be involved in the development of atopic dermatitis, but clinical usefulness of allergen-specific immunotherapy in the treatment of atopic dermatitis is controversial. We performed a pilot study to evaluate the clinical usefulness of combined treatment with allergen-specific immunotherapy and a histamine-immunoglobulin complex in patients with atopic dermatitis. Twenty patients with atopic dermatitis and hypersensitivity to house dust mites whose clinical conditions had not been effectively controlled by current standard medical therapies were treated with a combination of allergen-specific immunotherapy using house dust mite extract and a histamine-immunoglobulin complex for 12 months. The primary efficacy outcome was the change in the standardized clinical severity scoring system for atopic dermatitis (SCORAD) values at 6 and 12 months in comparison with the values at baseline. In 18 patients who completed all 12 months of treatment, the SCORAD values significantly decreased from 43.6 +/- 15.9 at baseline to 27.8 +/- 18.3 at 6 months and 18.3 +/- 14.9 at 12 months (Wilcoxon signed-rank test, p < 0.001), and no significant systemic side effects were observed. In this uncontrolled pilot study, combined treatment with allergen-specific immunotherapy and a histamine-immunoglobulin complex resulted in significant clinical improvements in patients with atopic dermatitis. However, double-blind placebo-controlled studies are necessary to test the clinical usefulness of this modified allergen-specific immunotherapy for atopic dermatitis.